Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01424111 · ClinicalTrials.gov registry record
Exploring Biomarkers for Depression
A clinical trial, sponsored by Wyss Institute at Harvard University.
- Completed
- Registry status
- 51
- Enrollment target
NCT01424111: Completed study, sponsored by Wyss Institute at Harvard University.
NCT01424111 is a clinical trial that has completed, run by Wyss Institute at Harvard University. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01424111 has completed, sponsored by Wyss Institute at Harvard University.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
Study Summary
The purpose of this research is to explore objective biomarkers in voice, physiological, motor, and brain imaging signals that may one day be used to complement clinical evaluation and treatment of depression.
Primary Outcome
Objective biomarkers in voice, physiological, motor and brain imaging signals
Interventions
- DRUG Escitalopram
- OTHER Healthy Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-08 |
| Est. Completion | 2017-10-14 |
What the finished NCT01424111 record still lists
NCT01424111 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Escitalopram is the first listed.
NCT01424111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01424111 about?
NCT01424111 is a clinical study titled "Exploring Biomarkers for Depression". The purpose of this research is to explore objective biomarkers in voice, physiological, motor, and brain imaging signals that may one day be used to complement clinical evaluation and treatment of depression.
What is the current status of trial NCT01424111?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2011-08. Estimated completion is 2017-10-14.
What interventions are being tested in trial NCT01424111?
The interventions under investigation include: Escitalopram (DRUG), Healthy Control (OTHER).
Who is sponsoring clinical trial NCT01424111?
This trial is sponsored by Wyss Institute at Harvard University, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia